Increased Interleukin-6 is Associated with Long COVID-19: Evidence from a Systematic Review and Meta-analysis
Abstract Background Coronavirus disease 2019 (COVID-19) can involve persistence, sequelae, and other medical complications that last weeks to months to evolve into long COVID-19. Exploratory studies have suggested that interleukin-6 (IL-6) is related to COVID-19; however, no correlation between IL-6 and long COVID-19 is known. We designed a systematic review and meta-analysis to assess the relationship between IL-6 levels and long COVID-19. Methods Databases were systematically searched for articles with data on long COVID-19 and IL-6 levels published before August 31, 2022. A total of 22 published studies were eligible for inclusion following the PRISMA guidelines. Analysis of data was undertaken by using Cochran's Q test and the Higgins I-squared (I2) statistic for heterogeneity. Random-effect meta-analyses were conducted to pool the IL-6 levels of long COVID-19 patients and to compare the differences in IL-6 levels among the long COVID-19, healthy, non-post-acute sequelae of SARS-CoV-2 infection (non-PASC), and acute COVID-19 populations. The funnel plot and Egger's test were used to assess potential publication bias. Sensitivity analysis was used to test the stability of the results. Results An increase in IL-6 levels was observed after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The pooled estimate of IL-6 revealed a mean value of 20.92 pg/ml (95% CI = 9.30–32.54 pg/ml, I2 = 100%, p < 0.01) for long COVID-19. The forest plot showed high levels of IL-6 levels with long COVID-19 compared to healthy controls (mean difference = 9.75 pg/ml, 95% CI = 5.75–13.75 pg/ml, I2 = 100%, p < 0.00001) and PASC category (mean difference = 3.32 pg/ml, 95% CI = 0.22–6.42 pg/ml, I2 = 88%, p = 0.04). The symmetry of the funnel plots was not obvious, and Egger’s test showed that there was no significant small study effect in all groups (long COVID-19 versus healthy controls, p = 0.24; long COVID-19 versus non-PASC, p = 0.31). Conclusions This study showed that increased IL-6 correlates with long COVID-19. Such an informative revelation suggests IL-6 as a basic determinant to predict long COVID-19 or at least inform on “early stage” of long COVID-19..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ResearchSquare.com - (2023) vom: 17. Okt. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yin, Jing-Xian [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
doi: |
10.21203/rs.3.rs-2166006/v1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XRA037897721 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XRA037897721 | ||
003 | DE-627 | ||
005 | 20231205145842.0 | ||
007 | cr uuu---uuuuu | ||
008 | 221117s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.21203/rs.3.rs-2166006/v1 |2 doi | |
035 | |a (DE-627)XRA037897721 | ||
035 | |a (ResearchSquare)10.21203/rs.3.rs-2166006/v1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yin, Jing-Xian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Increased Interleukin-6 is Associated with Long COVID-19: Evidence from a Systematic Review and Meta-analysis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Background Coronavirus disease 2019 (COVID-19) can involve persistence, sequelae, and other medical complications that last weeks to months to evolve into long COVID-19. Exploratory studies have suggested that interleukin-6 (IL-6) is related to COVID-19; however, no correlation between IL-6 and long COVID-19 is known. We designed a systematic review and meta-analysis to assess the relationship between IL-6 levels and long COVID-19. Methods Databases were systematically searched for articles with data on long COVID-19 and IL-6 levels published before August 31, 2022. A total of 22 published studies were eligible for inclusion following the PRISMA guidelines. Analysis of data was undertaken by using Cochran's Q test and the Higgins I-squared (I2) statistic for heterogeneity. Random-effect meta-analyses were conducted to pool the IL-6 levels of long COVID-19 patients and to compare the differences in IL-6 levels among the long COVID-19, healthy, non-post-acute sequelae of SARS-CoV-2 infection (non-PASC), and acute COVID-19 populations. The funnel plot and Egger's test were used to assess potential publication bias. Sensitivity analysis was used to test the stability of the results. Results An increase in IL-6 levels was observed after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The pooled estimate of IL-6 revealed a mean value of 20.92 pg/ml (95% CI = 9.30–32.54 pg/ml, I2 = 100%, p < 0.01) for long COVID-19. The forest plot showed high levels of IL-6 levels with long COVID-19 compared to healthy controls (mean difference = 9.75 pg/ml, 95% CI = 5.75–13.75 pg/ml, I2 = 100%, p < 0.00001) and PASC category (mean difference = 3.32 pg/ml, 95% CI = 0.22–6.42 pg/ml, I2 = 88%, p = 0.04). The symmetry of the funnel plots was not obvious, and Egger’s test showed that there was no significant small study effect in all groups (long COVID-19 versus healthy controls, p = 0.24; long COVID-19 versus non-PASC, p = 0.31). Conclusions This study showed that increased IL-6 correlates with long COVID-19. Such an informative revelation suggests IL-6 as a basic determinant to predict long COVID-19 or at least inform on “early stage” of long COVID-19. | ||
650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
700 | 1 | |a Agbana, Yannick Luther |4 aut | |
700 | 1 | |a Sun, Zhi-Shan |4 aut | |
700 | 1 | |a Fei, Si-Wei |4 aut | |
700 | 1 | |a Zhao, Han-Qing |4 aut | |
700 | 1 | |a Zhou, Xiao-Nong |4 aut | |
700 | 1 | |a Chen, Jun-Hu |4 aut | |
700 | 1 | |a Kassegne, Kokouvi |0 (orcid)0000-0002-7067-177X |4 aut | |
773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 17. Okt. |
773 | 1 | 8 | |g year:2023 |g day:17 |g month:10 |
856 | 4 | 0 | |u https://doi.org/10.1186/s40249-023-01086-z |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2166006/v1 |z kostenfrei |3 Volltext |
912 | |a GBV_XRA | ||
951 | |a AR | ||
952 | |j 2023 |b 17 |c 10 |